Vir Biotechnology, Inc. Q2 FY2025 earnings call

Key accomplishments include progress in ECLIPSE registrational programs for hepatitis delta with all 3 studies recruiting; initiation of Phase I study for VIR-5525 EGFR-targeted T cell engager; progress in VIR-5818 and VIR-5500 T cell engager programs; strong financial position with ~$892M in cash, cash equivalents and investments at quarter end.

No specific financial performance data provided for product segments; key progress in hepatitis delta ECLIPSE registrational programs and oncology T cell engager programs.

Focus on driving enrollment in ECLIPSE studies, advancing clinical stage T cell engager programs, and executing business development strategies; cash runway extends into mid-2027.

Risks associated with clinical development programs, potential differences from forward-looking statements, challenges in estimating HDV patient population, competitive landscape impacts.

Q: Enrollment update on ECLIPSE programs and TAM prep work; A: ECLIPSE 1 enrollment going well, ECLIPSE 2 and 3 just started; estimating ~61k viremic HDV patients in US but likely underestimate.

Q: ECLIPSE 1 primary completion and TCE program dosing; A: Primary completion for ECLIPSE 1 expected by Dec 2026; starting dose of 5525 based on regulatory standard, preclinical data shows wide therapeutic margin.

Q: Additional data cuts from SOLSTICE study and 5500 data; A: Plan to provide complete 48-week SOLSTICE data by end of year; no specific guidance on 5500 next data cut.

Q: ECLIPSE registration and TCE program updates; A: Base case for US registration is ECLIPSE 1 and 2; updates for 5818 and 5500 to come when data is ready.

Q: ECLIPSE 2 enrollment and 5518 data release; A: ECLIPSE 2 enrollment of bulevirtide non-responders straightforward; decision on 5518 data release pending.

Q: Hepatitis delta competitive landscape and combo approach; A: Gilead refiling bulevirtide positive for market education; combo approach offers high viral suppression and convenience.

Q: 5500 patient enrollment and less frequent dosing; A: Enrolling first-in-human patients, planning early line expansion; less frequent dosing shown effective in HER2 program.

Q: ECLIPSE 1 deferred treatment and 5525 program design; A: 12-week deferred treatment rationale for patient friendliness; 5525 works regardless of KRAS mutations via T cell redirect.

Q: ECLIPSE 1 deferred treatment rationale; A: 12-week deferred treatment acceptable as delta virus doesn't spontaneously clear, patient-friendly design.